{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:01:56Z","timestamp":1793307716154,"version":"4.5.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32-CA009531"],"award-info":[{"award-number":["T32-CA009531"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R37 CA291896"],"award-info":[{"award-number":["R37 CA291896"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R50 CA211404"],"award-info":[{"award-number":["R50 CA211404"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","award":["P30 CA022453"],"award-info":[{"award-number":["P30 CA022453"]}],"id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008884","name":"Edward P. Evans Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006710","name":"Wayne State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016394","name":"Ludwig Center at Harvard","doi-asserted-by":"publisher","award":["R33CA278393"],"award-info":[{"award-number":["R33CA278393"]}],"id":[{"id":"10.13039\/100016394","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014084","name":"Vera and Joseph Dresner Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014084","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007427","name":"MPN Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007427","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017302","name":"Barbara Ann Karmanos Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017302","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032616","name":"Starr Cancer Consortium","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032616","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008552","name":"Brigham Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008552","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.bneo.2026.100202","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T23:15:03Z","timestamp":1770333303000},"page":"100202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Synergistic targeting of eIF4A-mediated translation initiation and apoptosis in acute myeloid leukemia"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0090-0079","authenticated-orcid":false,"given":"Yoke Seng","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4086-5709","authenticated-orcid":false,"given":"Jonathan D.","family":"Good","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha","family":"Awais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin K.","family":"Eschle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maia S.","family":"Lineberry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3541-1861","authenticated-orcid":false,"given":"Jingting","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2166-5146","authenticated-orcid":false,"given":"Mark","family":"Wunderlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Thibodeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8171-4763","authenticated-orcid":false,"given":"Jessica L.","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0975-4443","authenticated-orcid":false,"given":"Sarah","family":"Bibeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Wollman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4095-0141","authenticated-orcid":false,"given":"George","family":"Karadimov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2603-0182","authenticated-orcid":false,"given":"Nurefsan","family":"Sariipek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basit","family":"Salik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3506-4042","authenticated-orcid":false,"given":"Jean","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Noel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6706-5464","authenticated-orcid":false,"given":"David G. J.","family":"Cucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2430-6982","authenticated-orcid":false,"given":"Erica A. K.","family":"DePasquale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prafulla C.","family":"Gokhale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5526-4669","authenticated-orcid":false,"given":"Jerome","family":"Ritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8748-716X","authenticated-orcid":false,"given":"Yubin","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6797-9335","authenticated-orcid":false,"given":"Peter G.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi J.","family":"Najm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2118-6302","authenticated-orcid":false,"given":"Jacqueline S.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7380-0226","authenticated-orcid":false,"given":"Andrew A.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney L.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0735-1570","authenticated-orcid":false,"given":"Peter","family":"van Galen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bneo.2026.100202_bib1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1146\/annurev-cancerbio-060220-124048","article-title":"The intriguing clinical success of BCL-2 inhibition in acute myeloid leukemia","volume":"5","author":"Pollyea","year":"2021","journal-title":"Annu Rev Cancer Biol"},{"issue":"7","key":"10.1016\/j.bneo.2026.100202_bib2","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.bneo.2026.100202_bib3","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable residual disease response and prognosis in treatment-na\u00efve acute myeloid leukemia with venetoclax and azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bneo.2026.100202_bib4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.stem.2014.02.006","article-title":"Evolution of the cancer stem cell model","volume":"14","author":"Kreso","year":"2014","journal-title":"Cell Stem Cell"},{"issue":"23","key":"10.1016\/j.bneo.2026.100202_bib5","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bneo.2026.100202_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2019.01.031","article-title":"Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity","volume":"176","author":"van Galen","year":"2019","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.bneo.2026.100202_bib7","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/s41591-022-01819-x","article-title":"A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia","volume":"28","author":"Zeng","year":"2022","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.bneo.2026.100202_bib8","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","article-title":"Combinatorial BCL2 family expression in acute myeloid leukemia stem cells predicts clinical response to azacitidine\/venetoclax","volume":"13","author":"Waclawiczek","year":"2023","journal-title":"Cancer Discov"},{"issue":"8041","key":"10.1016\/j.bneo.2026.100202_bib9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41586-024-08137-x","article-title":"RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax","volume":"636","author":"Sango","year":"2024","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bneo.2026.100202_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.525","article-title":"MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies","volume":"6","author":"Choudhary","year":"2015","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.bneo.2026.100202_bib11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","article-title":"Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.bneo.2026.100202_bib12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-025-01215-x","article-title":"Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention","volume":"15","author":"Fonseca","year":"2025","journal-title":"Blood Cancer J"},{"issue":"674","key":"10.1016\/j.bneo.2026.100202_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo6891","article-title":"The path to venetoclax resistance is paved with mutations, metabolism, and more","volume":"14","author":"Sullivan","year":"2022","journal-title":"Sci Transl Med"},{"issue":"7","key":"10.1016\/j.bneo.2026.100202_bib14","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","article-title":"Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment","volume":"9","author":"Chen","year":"2019","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.bneo.2026.100202_bib15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13046-024-03267-6","article-title":"ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress","volume":"44","author":"Carter","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.bneo.2026.100202_bib16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd4505","article-title":"Targeting the translation machinery in cancer","volume":"14","author":"Bhat","year":"2015","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.bneo.2026.100202_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2018.10.021","article-title":"Integrated stress response activity marks stem cells in normal hematopoiesis and leukemia","volume":"25","author":"van Galen","year":"2018","journal-title":"Cell Rep"},{"issue":"6","key":"10.1016\/j.bneo.2026.100202_bib18","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nsmb.2303","article-title":"A mechanistic overview of translation initiation in eukaryotes","volume":"19","author":"Aitken","year":"2012","journal-title":"Nat Struct Mol Biol"},{"issue":"10","key":"10.1016\/j.bneo.2026.100202_bib19","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1186\/s13059-014-0476-1","article-title":"Transcriptome-wide characterization of the eIF4A signature highlights plasticity in translation regulation","volume":"15","author":"Rubio","year":"2014","journal-title":"Genome Biol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100202_bib20","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1038\/s41467-019-13086-5","article-title":"eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma","volume":"10","author":"Chan","year":"2019","journal-title":"Nat Commun"},{"issue":"6143","key":"10.1016\/j.bneo.2026.100202_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/science.1238303","article-title":"Tight coordination of protein translation and HSF1 activation supports the anabolic malignant state","volume":"341","author":"Santagata","year":"2013","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bneo.2026.100202_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.528","article-title":"The traditional Chinese medical compound Rocaglamide protects nonmalignant primary cells from DNA damage-induced toxicity by inhibition of p53 expression","volume":"5","author":"Becker","year":"2014","journal-title":"Cell Death Dis"},{"issue":"8","key":"10.1016\/j.bneo.2026.100202_bib23","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1002\/ijc.28521","article-title":"The natural anticancer compound rocaglamide selectively inhibits the G1-S-phase transition in cancer cells through the ATM\/ATR-mediated Chk1\/2 cell cycle checkpoints","volume":"134","author":"Neumann","year":"2014","journal-title":"Int J Cancer"},{"issue":"7516","key":"10.1016\/j.bneo.2026.100202_bib24","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nature13485","article-title":"RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer","volume":"513","author":"Wolfe","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bneo.2026.100202_bib25","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41375-019-0503-z","article-title":"Targeting translation initiation by synthetic rocaglates for treating MYC-driven lymphomas","volume":"34","author":"Zhang","year":"2020","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.bneo.2026.100202_bib26","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1038\/s41375-021-01308-z","article-title":"Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML","volume":"35","author":"Nishida","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bneo.2026.100202_bib27","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s13046-022-02542-8","article-title":"EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax","volume":"41","author":"Fooks","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.bneo.2026.100202_bib28","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.1021\/acs.jmedchem.0c00182","article-title":"Design of development candidate eFT226, a first in class inhibitor of eukaryotic initiation factor 4A RNA helicase","volume":"63","author":"Ernst","year":"2020","journal-title":"J Med Chem"},{"issue":"suppl 16","key":"10.1016\/j.bneo.2026.100202_bib29","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1200\/JCO.2022.40.16_suppl.3081","article-title":"First-in-human phase 1\/2 dose escalation and expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with solid tumors","volume":"40","author":"Meric-Bernstam","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.bneo.2026.100202_bib30","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2023.41.16_suppl.1080","article-title":"Phase 1\/2 dose expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with ER+ metastatic breast cancer","volume":"41","author":"Rosen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.bneo.2026.100202_bib31","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167651","article-title":"Cotargeting a MYC\/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer","volume":"133","author":"Nardi","year":"2023","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.bneo.2026.100202_bib32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0973","article-title":"Targeting oncogene mRNA translation in B-cell malignancies with eFT226, a potent and selective inhibitor of eIF4A","volume":"20","author":"Thompson","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.bneo.2026.100202_bib33","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1038\/s41467-018-05984-x","article-title":"Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes","volume":"9","author":"Stevens","year":"2018","journal-title":"Nat Commun"},{"issue":"16","key":"10.1016\/j.bneo.2026.100202_bib34","doi-asserted-by":"crossref","DOI":"10.1172\/JCI153514","article-title":"Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells","volume":"28","author":"Sellar","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bneo.2026.100202_bib35","author":"DepMap"},{"issue":"2","key":"10.1016\/j.bneo.2026.100202_bib36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s43018-019-0018-6","article-title":"Discovering the anticancer potential of non-oncology drugs by systematic viability profiling","volume":"1","author":"Corsello","year":"2020","journal-title":"Nat Cancer"},{"issue":"1","key":"10.1016\/j.bneo.2026.100202_bib37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cell.2016.02.066","article-title":"Ribosome footprint profiling of translation throughout the genome","volume":"165","author":"Ingolia","year":"2016","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bneo.2026.100202_bib38","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41467-023-36290-w","article-title":"Reanalysis of ribosome profiling datasets reveals a function of rocaglamide A in perturbing the dynamics of translation elongation via eIF4A","volume":"14","author":"Li","year":"2023","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.bneo.2026.100202_bib39","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100202_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/cpmb.108","article-title":"DeltaTE: detection of translationally regulated genes by integrative analysis of Ribo-seq and RNA-seq data","volume":"129","author":"Chothani","year":"2019","journal-title":"Curr Protoc Mol Biol"},{"issue":"31","key":"10.1016\/j.bneo.2026.100202_bib41","doi-asserted-by":"crossref","first-page":"5301","DOI":"10.1038\/sj.onc.1207692","article-title":"MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol","volume":"23","author":"Domina","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.bneo.2026.100202_bib42","article-title":"Targeting MCL-1\/BCL-XL forestalls the acquisition of resistance to ABT-199 in acute myeloid leukemia","volume":"6","author":"Lin","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.bneo.2026.100202_bib43","article-title":"Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells","volume":"2","author":"Luedtke","year":"2017","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"10.1016\/j.bneo.2026.100202_bib44","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3390\/antiox11030461","article-title":"Venetoclax-resistant MV4-11 leukemic cells activate PI3K\/AKT pathway for metabolic reprogramming and redox adaptation for survival","volume":"11","author":"Alkhatabi","year":"2022","journal-title":"Antioxidants (Basel)"},{"issue":"7954","key":"10.1016\/j.bneo.2026.100202_bib45","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.bneo.2026.100202_bib46","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood.2025028357","article-title":"Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study","volume":"146","author":"Arellano","year":"2025","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.bneo.2026.100202_bib48","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-19-0832","article-title":"Inhibition of Bcl-2 synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-mutated acute myeloid leukemia","volume":"25","author":"Ma","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"101354","key":"10.1016\/j.bneo.2026.100202_bib49","article-title":"Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD\/D835 mutant AML","volume":"18","author":"Yamatani","year":"2022","journal-title":"Transl Oncol"},{"issue":"7633","key":"10.1016\/j.bneo.2026.100202_bib50","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nature20598","article-title":"A 17-gene stemness score for rapid determination of risk in acute leukaemia","volume":"540","author":"Ng","year":"2016","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.bneo.2026.100202_bib51","doi-asserted-by":"crossref","first-page":"5402","DOI":"10.1182\/bloodadvances.2020001802","article-title":"CD200 expression marks leukemia stem cells in human AML","volume":"4","author":"Ho","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.bneo.2026.100202_bib52","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002968","article-title":"Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML","volume":"9","author":"Herbrich","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.bneo.2026.100202_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.766298","article-title":"Zotatifin, an eIF4A-selective inhibitor, blocks tumor growth in receptor tyrosine kinase driven tumors","volume":"11","author":"Gerson-Gurwitz","year":"2021","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.bneo.2026.100202_bib54","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1038\/s41375-019-0612-8","article-title":"How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia","volume":"33","author":"Jonas","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bneo.2026.100202_bib55","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cell.2015.05.049","article-title":"Differential requirements for eIF4E dose in normal development and cancer","volume":"162","author":"Truitt","year":"2015","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.bneo.2026.100202_bib56","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2013.25","article-title":"Modifying chemotherapy response by targeted inhibition of eukaryotic initiation factor 4A","volume":"3","author":"Cencic","year":"2013","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.bneo.2026.100202_bib57","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.leukres.2009.07.043","article-title":"Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells","volume":"34","author":"Cencic","year":"2010","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.bneo.2026.100202_bib58","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1182\/blood.2020008676","article-title":"CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells","volume":"137","author":"Surka","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bneo.2026.100202_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.02.002","article-title":"Rocaglates induce gain-of-function alterations to eIF4A and eIF4F","volume":"30","author":"Chu","year":"2020","journal-title":"Cell Rep"},{"issue":"4","key":"10.1016\/j.bneo.2026.100202_bib60","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2318093121","article-title":"A second-generation eIF4A RNA helicase inhibitor exploits translational reprogramming as a vulnerability in triple-negative breast cancer","volume":"121","author":"Cencic","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.bneo.2026.100202_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2020.07.021","article-title":"Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells","volume":"27","author":"Jones","year":"2020","journal-title":"Cell Stem Cell"},{"issue":"12","key":"10.1016\/j.bneo.2026.100202_bib62","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","article-title":"Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells","volume":"1","author":"Stevens","year":"2020","journal-title":"Nat Cancer"},{"issue":"115759","key":"10.1016\/j.bneo.2026.100202_bib63","article-title":"Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: in vitro models and mechanisms","volume":"216","author":"Carter","year":"2023","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"10.1016\/j.bneo.2026.100202_bib64","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.bneo.2026.100202_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2020.10.010","article-title":"Reduced mitochondrial apoptotic priming drives resistance to BH3 mimetics in acute myeloid leukemia","volume":"38","author":"Bhatt","year":"2020","journal-title":"Cancer Cell"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:27:51Z","timestamp":1779294471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328026000130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2950328026000130"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100202","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic targeting of eIF4A-mediated translation initiation and apoptosis in acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100202","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100202"}}